Veliparib (ABT-888)

Catalog No.S1004 Synonyms: NSC 737664

Veliparib (ABT-888) Chemical Structure

Molecular Weight(MW): 244.29

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

Size Price Stock Quantity  
In DMSO USD 156 In stock
USD 120 In stock
USD 370 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 40 Publications

9 Customer Reviews

  • (A) OVCAR-8 cells were exposed to the indicated concentrations of FdUrd along with vehicle, 3 μM ABT-888 or 300 nM AZD2281 for 24 h. Following washing, ABT-888 and AZD2281 were re-added to the plates initially exposed to these agents, and cells were cultured in the continued presence of ABT-888 and AZD2281 for 8 d until colonies formed. (B) OVCAR-8 cells were exposed continuously to the indicated agents for 8 d. (C) OVCAR-8 cells treated as in (A) except that the indicated concentrations of ABT-888 were used.

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

    OVCAR-8 cells were plated, treated with indicated concentrations of FdUrd and 3 μM ABT-888 using the exposure schemes depicted in (C) and assayed for clonogenicity (D).

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046-1051. Veliparib (ABT-888) purchased from Selleck.

    Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

  • Colorimetric poly(ADP-ribose) polymerase (PARP) activity assay showing the relative activity of the PARP-1 enzyme in Raji lymphocyte tumor cells. Results show a highly significant difference in PARP activity in the controls [PBS and dimethyl sulfoxide (DMSO)] compared with 24 h incubation with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281. A significant increase in PARP enzyme activity is shown in DMSO-incubated cells compared with PBS control.* P < 0.05.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

    T47D breast cancer cells were pretreated with indicated concentrations of ABT-888

     

     

    Dr.Zhang of Tianjin Medical University. Veliparib (ABT-888) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor ABT-888 upon induction of DNA damage

    Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor ABT-888 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor.
    Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.
     
     

     

    David Schrmann from University of Base. Veliparib (ABT-888) purchased from Selleck.

    Caption:  451 Lu is a melanoma cell line with high PARP expression that is resistant to temozolomide.  Treatment with 25 µM ABT-888 greatly increased sensitivity to temozolomide compared to cells without ABT-888 treatment as measured by MTS assay.

     

     

    Dr. Steve Reuland from University of Colorado Denver. Veliparib (ABT-888) purchased from Selleck.

  • Effect of ABT-888 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     
     

     

    Dr. Xiangbing Meng of University of Iowa. Veliparib (ABT-888) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.
Features Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
In vitro

ABT-888 is inactive to SIRT2 (>5 μM). [1] ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. [2] ABT-888 could decrease the PAR levels in both irradiated and nonirradiated H460 cells. ABT-888 also reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. ABT-888 increases apoptosis and autophagy in H460 cells when combination with radiation. [3] ABT-888 also inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. ABT-888 (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. ABT-888 shows effective radiosensitivity in oxic H1299 cells. Furthermore, ABT-888 could attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 MWXLbY5ie2ViQYPzZZk> MmXrN|AhdWmw MnXpTY5pcWKrdHnvckBw\iCSQWLQNUB4cXSqIFXDOVAhd2ZiMD6wNFIh|ryP NXzVb3FvOTl6OEi3OlA>
Jurkat MU\LbY5ie2ViQYPzZZk> MXu5OkBp M3LVXmROW09? MnThTY5pcWKrdHnvckBw\iCSQWLQNUBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gZ4VtdCC4aXHibYxqfHlid3n0bEBGSzVyIH;mJFMh|ryP NUP0RWZvOjN6NUCxPVk>
Capan1 NWj1OJZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\FO|IhcA>? M3zt[mROW09? NYrocoxSSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBDWkODMjDn[Y5mKG23dHH0[YQhcHWvYX6gR4Fx[W5zIHPlcIx{KHerdHigTWM2OCCxZjCzPU44KM7:TR?= NYKyO3pbOjR|OUizPFM>
DT40 MVfDfZRwfG:6aXOgRZN{[Xl? M17Q[VczKGh? M{XM[WROW09? NV7LeFhLS3m2b4TvfIlkcXS7IHHnZYlve3RiY3jpZ4tmdiCEUlPBNk1l\W[rY3nlcpQhTFR2MDDj[Yxtew>? NFTTenUzPDl{MkW4Oy=>
ML-1 NVzhdIxbSXCxcITveIlkKEG|c3H5 NYrsZml7Oi53IN88US=> NUPJUnhyOjRiaB?= NGr2PWlFVVOR MYXTfY5memerc4TpZ4FtdHliZX7oZY5k\XNiVGLBTWwucW6mdXPl[EBieG:ydH;zbZMhcW5iTVytNUBk\Wyucx?= NHP3RWMzPDh7NUGzOS=>
HCT-116 NEDrflBMcW6jc3WgRZN{[Xl? M{L2PFAvPSEQvF2= MUOyOEBp MX;QRXJRKGGldHn2bZR6KGSnY4LlZZNmew>? MmntNlMxPTR{MUO=
UM-SCC1 NIrtWIREgXSxdH;4bYMhSXO|YYm= MXKxNEDPxE1? Ml7vNlQhcA>? NHiye2VT\WS3Y3XzJJRp\SClZXzsJJZq[WKrbHn0fS=> NXzO[2xnOjF7MUK2NlA>
FaDu MWDDfZRwfG:6aXOgRZN{[Xl? MWSxNEDPxE1? MWCyOEBp NYXORoVOWmWmdXPld{B1cGViY3XscEB3cWGkaXzpeJk> MkH5NlE6OTJ4MkC=
PC-3 NXvQe5J[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XwV|ExKM7:TR?= M1fKNWlv\HWlZYOgZUB{cWewaX\pZ4FvfCCrbnjpZol1cW:wIHnuJINwdG:weTDmc5Ju[XSrb39CpC=> MnrkNlE2PzF7MUK=
EoL-1-cell NVvl[4NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PQ[GlEPTB;MT6wO|k5KM7:TR?= MkDXV2FPT0WU
NCI-SNU-5 MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTNwMUK4OFEh|ryP M3vVd3NCVkeHUh?=
BV-173 M{WyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFy2Z4ZKSzVyPUWuOFU1ODlizszN Mm\GV2FPT0WU
HCC1806 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHF[m1KUUN3ME21Mlc2OTd|IN88US=> NHvrdWhUSU6JRWK=
COLO-680 Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm0ZolKSzVyPU[uNlE1ODZizszN MlzGV2FPT0WU
HCC2218 NXPtVYRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DuU2lEPTB;Nz63PVcxPCEQvF2= M3\reXNCVkeHUh?=
SK-MEL-24 NUXObIpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTpTWM2OD15LkixPVI1KM7:TR?= MX7TRW5ITVJ?
NCI-H720 MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRThwNEO2NFMh|ryP Mn7mV2FPT0WU
KASUMI-1 M1rsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TTdGlEPTB;OD64PVI3PiEQvF2= MlnFV2FPT0WU
HAL-01 M1v1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\aPGlEPTB;OT64PFYzKM7:TR?= NHHENFVUSU6JRWK=
CAL-33 NYLQOGpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFyLkSzOEDPxE1? MnrIV2FPT0WU
SK-MEL-1 MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLHWXFKSzVyPUGyMlQ3PjNizszN NX2yfpdkW0GQR1XS
Ramos-2G6-4C10 M3u1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGC4NJBKSzVyPUGyMlQ4PTJizszN M4PpT3NCVkeHUh?=
KY821 NU\3fldLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq1VFlyUUN3ME2xNk41QDVizszN NVL4ZlFKW0GQR1XS
HEC-1 NH6yb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4WxbmlEPTB;MUKuPVE6PiEQvF2= MnnjV2FPT0WU
SK-NEP-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfacmpKSzVyPUGzMlE3PiEQvF2= M{fmfHNCVkeHUh?=
MN-60 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTF|LkWzPFkh|ryP NUHD[|JtW0GQR1XS
DU-145 M2P3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF|LkmwOVMh|ryP NWrLOYF3W0GQR1XS
EW-3 NYTYVYdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkH1TWM2OD1zND61OVY2KM7:TR?= NUP5XYtpW0GQR1XS
OS-RC-2 M1nacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\QZ3ltUUN3ME2xOU46PTh7IN88US=> Ml;tV2FPT0WU
RPMI-8226 NH\y[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfFRohKSzVyPUG2MlIxPDJizszN MUTTRW5ITVJ?
ChaGo-K-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDVTWM2OD1zNj61N|I2KM7:TR?= MXnTRW5ITVJ?
DEL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmKzTWM2OD1zNj62O|E4KM7:TR?= NX7DWpVYW0GQR1XS
GP5d MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTF5LkC1N{DPxE1? M4f6[HNCVkeHUh?=
COLO-668 NGf4WWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTF5Lk[yPVQh|ryP MlPRV2FPT0WU
H9 MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF6LkK4N|Mh|ryP M3L5bXNCVkeHUh?=
NKM-1 MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2OwWWlEPTB;MUiuOVEyQSEQvF2= MWfTRW5ITVJ?
KYSE-150 MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M135bmlEPTB;MUiuPVk5PiEQvF2= NV3Ebml[W0GQR1XS
Daoy MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3YUZplUUN3ME2xPU42PjR7IN88US=> MWfTRW5ITVJ?
ECC10 NH\Dc4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLuTWM2OD1{MD63OFU2KM7:TR?= MmjMV2FPT0WU
A388 NF\HXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TrPGlEPTB;MkGuPVA6OSEQvF2= NIHuTXdUSU6JRWK=
MHH-NB-11 NYLFT3M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mme2TWM2OD1{Mz6xN|Y{KM7:TR?= M1\u[XNCVkeHUh?=
HCC1937 NYnOb|dUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJ2Lke0OkDPxE1? M4jLRnNCVkeHUh?=
TGBC11TKB Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{i1e2lEPTB;MkWuOlg3OyEQvF2= NULieGZnW0GQR1XS
CTV-1 MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJ3Lki5Olkh|ryP MXjTRW5ITVJ?
NCI-H2029 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{SwN2lEPTB;Mk[uOFI{QCEQvF2= NWfl[nkyW0GQR1XS
HLE MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDVWm9KSzVyPUK3MlA2PCEQvF2= M1LRT3NCVkeHUh?=
NCI-H1693 M1;aS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPsTWM2OD1{Nz6yPFk5KM7:TR?= NFK1eo5USU6JRWK=
HCC70 Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFq0bGVKSzVyPUK3MlczPDZizszN MU\TRW5ITVJ?
BEN Mm\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVniWZhQUUN3ME2yO{46PTZ4IN88US=> NV6zbG56W0GQR1XS
LB771 NXzUS|VUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7VTI9KSzVyPUK4Mlg{PzNizszN M1\xdXNCVkeHUh?=
697 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO4N3FKSzVyPUK5MlAzOzVizszN MX3TRW5ITVJ?
LU-139 NFfveWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfYTWM2OD1{OT6zO|Q5KM7:TR?= NHn6V|dUSU6JRWK=
EW-13 M1vlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPrTWM2OD1{OT6zPFE1KM7:TR?= NYXxXoFMW0GQR1XS
MOLT-13 M4OyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofzTWM2OD1{OT6zPFE1KM7:TR?= M3zOW3NCVkeHUh?=
L-363 NYf0U|RsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJ7LkS3PVgh|ryP NE\PNVdUSU6JRWK=
EM-2 MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\LU2lEPTB;MkmuOFkxOSEQvF2= MX\TRW5ITVJ?
RS4-11 MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXvRlBKSzVyPUOwMlQzPDFizszN NYC5NXhUW0GQR1XS
A2780 NHjYZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3pUG1jUUN3ME2zNE44PDV5IN88US=> M3vEbXNCVkeHUh?=
KU812 Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq4TXR5UUN3ME2zNk4{PjR{IN88US=> M1PTOnNCVkeHUh?=
COLO-684 NYPZdW5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vvVmlEPTB;M{OuN|U6QSEQvF2= NUHUcGd6W0GQR1XS
MFE-280 NFOwOlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorRTWM2OD1|Mz6zPFg6KM7:TR?= NYG2TFFDW0GQR1XS
KG-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\RR2lEPTB;M{OuOlAxOSEQvF2= M{DkUHNCVkeHUh?=
JVM-3 NYrOTXdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkT5TWM2OD1|NT61PFY5KM7:TR?= NWrTPYppW0GQR1XS
MV-4-11 M3r1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvEcm1KSzVyPUO1Mlg1QTlizszN NIexb5lUSU6JRWK=
LAMA-84 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIqxVlRKSzVyPUO2Mlc{PDVizszN NXzJcpB6W0GQR1XS
MOLT-16 Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf5TWM2OD1|Nj65OVIh|ryP MoDwV2FPT0WU
H4 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnizTWM2OD1|Nz61Olch|ryP NUL3OYNkW0GQR1XS
T47D NVrNN2t3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTN5LkewNVgh|ryP NUSzbVF5W0GQR1XS
CAL-54 NF34c|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnrO5JEUUN3ME2zO{46PjZizszN NVXO[otkW0GQR1XS
SW982 M3T6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTN6LkC5PVgh|ryP NITmSmRUSU6JRWK=
IGROV-1 MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITDeWJKSzVyPUO5MlM{ODRizszN MUPTRW5ITVJ?
NB14 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3BeXdDUUN3ME20NE44ODNzIN88US=> MmnpV2FPT0WU
HCC1187 NWfR[IlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTRzLkK3O|Eh|ryP M3LXUnNCVkeHUh?=
SBC-1 NFzOSFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnexTWM2OD12MT6zNFY{KM7:TR?= NGnSOGxUSU6JRWK=
KARPAS-45 NGC4fpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37GS2lEPTB;NEGuOFgyQCEQvF2= M3;LOnNCVkeHUh?=
MOLT-4 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTR{LkK1N|gh|ryP NFvKe3lUSU6JRWK=
JVM-2 NEPmZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nKOWlEPTB;NEKuPVIxPyEQvF2= NG\SUXRUSU6JRWK=
A4-Fuk NETmUGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\OSVRtUUN3ME20N{42PjlzIN88US=> M1XzfnNCVkeHUh?=
MDA-MB-361 NVXFWnF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTR|Lki0NVQh|ryP Ml7NV2FPT0WU
BALL-1 NEL6NYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWT0V5ozUUN3ME20N{46PTN{IN88US=> NIjJNGJUSU6JRWK=
T98G MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DCRmlEPTB;NESuPFUyPyEQvF2= NVPIfnNFW0GQR1XS
Mo-T MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jqNGlEPTB;NEWuOlM5QSEQvF2= NXXi[ZFEW0GQR1XS
MHH-PREB-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfn[mpKSzVyPUS1Mlc2QDVizszN MYXTRW5ITVJ?
ALL-PO MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXxXYpKSzVyPUS3MlM4QTFizszN NHLKT4pUSU6JRWK=
NCI-H510A MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfKPZFKSzVyPUS3MlkxOzRizszN M2ruXnNCVkeHUh?=
ML-2 M3q0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTR7Lke4OVYh|ryP Mn[wV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo The oral bioavailability of ABT-888 is 56%-92% in mice, Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys after oral administration. [1] ABT-888 (25 mg/kg i.p.) could improve tumor growth delay in a NCI-H460 xenograft model with well tolerated. Combination with radiation, ABT-888 decreases the tumor vessel formation. [3] ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression could be maintained over time. [4]

Protocol

Animal Research:

[1]

+ Expand
  • Animal Models: NCI-H460, H460, B16F10 and 9L xenografts in C57BL/6 mice
  • Formulation: Formulated in solution containing 0.9% NaCl adjusted to pH 4.0
  • Dosages: ~25 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (69.58 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 0.5% methylcellulose+0.2% Tween 80 5 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.29
Formula

C13H16N4O

CAS No. 912444-00-9
Storage powder
in solvent
Synonyms NSC 737664

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00553189 Completed Solid Tumors|Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9, 2007 Phase 1
NCT03032614 Not yet recruiting Breast Cancer Stage IV|Ovarian Cancer|BRCA1 Mutation|BRCA2 Mutation The University of Texas Health Science Center at San Antonio March 31, 2017 Phase 2
NCT01445522 Completed Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 3, 2008 Phase 1
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1
NCT02723864 Recruiting Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 22, 2016 Phase 1
NCT00994071 Completed Medulloblastoma|Pontine Glioma|Ependymoma|Astrocytoma|PNET National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) September 22, 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Veliparib (ABT-888) | Veliparib (ABT-888) supplier | purchase Veliparib (ABT-888) | Veliparib (ABT-888) cost | Veliparib (ABT-888) manufacturer | order Veliparib (ABT-888) | Veliparib (ABT-888) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID